The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation

Journal of Inflammation

Table 2 Transplantation and CCR5 polymorphism

No. of patients	Setting of transplantation	Genotyping Recipients (R)/Donor (D)	Outcome	Ref.
Hematopoietic stem cell transplantation
1370	HSCT (MURD)	(R): CCR5(H1/H1)	DFS ↑, OS ↑	[33]
		(D): CCR5(H1/H1)	DFS ↓
349	HSCT (MURD & MRD)	(R): CCR5-delta32	GvHD ↓	[19]
		(D): CCR5-delta32	No acute GvHD*
1273	HSCT (MURD)	(R): nd		[54]
		(D): CCR5-delta32	GvHD ↓**
Solid organ transplantation
158	Liver	(R): CCR5-delta32	AR ↓	[55]
		(D): nd
1227	Kidney	(R): CCR5-delta32	Allograft Survival ↑	[18]
		(D): nd
163	Kidney	(R): CCR5-59029-A/G	AR ↓	[56]
		(D): nd
158	Heart	(R): CCR5 No-E	EAR ↓	[57]
		(D): nd

Summary of clinical trials focusing on the outcome of allogeneic stem cell or tissue transplantation in regard to different CCR5 polymorphism. In most cases, CCR5 genotyping was only performed in recipients. (HSCT = hematopoietic stem cell transplantation, MURD = matched unrelated donor, MRD = matched related donor, nd = not done, DFS = disease free survival, OS = overall survival, GVHD = graft-versus-host disease, AR = acute rejection, EAR = early acute rejection)
* in the case of CCR5-delta32 for both donor and recipient, respectively.
** not significant

ISSN: 1476-9255